Skip navigation
Watchlist Sponsored By :

As of Friday, November 13th:
The blended earnings growth rate for the S&P 500 for Q3 2009, combining actual numbers for companies that have reported, and estimates for companies yet to report rose to -13.8% from -13.9% in the previous day.
As of October 1st, the earnings growth rate was at -24.7%.Of the 463 S&P 500 companies who have reported Q3, 80% beat estimates, 6% were in-line, and 14% were below estimates.  The blended earnings growth rate for the S&P 500 for Q3 2009 is currently at -13.8%. (Data provided by Thomson Reuters)

LATEST EARNINGS RESULTS


Current DateTime: 06:29:13 16 Nov 2009
LinksList Documentid: 29017166
Expiration DateTime: 11/16/2009 6:30:26 PM

Current DateTime: 06:29:14 16 Nov 2009
LinksList Documentid: 24355697

FEATURED QUIZZES


Current DateTime: 06:29:14 16 Nov 2009
LinksList Documentid: 33793611
  • How Much Do You Know About Green?

      Green has become part of our everyday lives. Green is everywhere-- energy, clothing, food, housing, transportation. It's a big business and a global business.

  • The Billionaire BFF's

      Philanthropists. Bridge partners. Hockey players. Which responses are based on facts from Buffett's and Gates' real lives?

  • The Many Myths of Coca-Cola

      Can you tell which statements are true, and which ones are just rumors?


Current DateTime: 06:29:14 16 Nov 2009
LinksList Documentid: 24890560
  • Winterizing Your Portfolio

      If 2009 was the winter of our discontent, will 2010 be a winter wonderland for investors? A lot depends on the recovery—or lack thereof.

  • Investor's Guide to Real Estate

      Some even say the long-awaited recovery is here. Regardless, buyers and sellers alike can profit from our guide.

  • Alternative Investing

      Stocks and bonds? Sure. But it's a big world out there for investors.

powered by digg
Bloodthinner Plavix Gets Big Boost in New  Study
By: Mike Huckman,, CNBC Pharmaceuticals Reporter | 05 Feb 2008 | 04:37 PM ET
Text Size

Heart patients with drug-coated stents who stop taking the popular bloodthinner Plavix are quickly put at a higher risk of death, according to a new study published in the "Journal of the American Medical Association."

The finding could boost sales of the blockbuster drug made by Bristol-Myers Squibb [BMY  Loading...      ()   ] and Sanofi-Aventis [SNY  Loading...      ()   ].

Drug-coated stents prop open clogged arteries, but some studies say that months or years later potentially fatal blood clots form.  Patients are put on Plavix to help prevent that.

Researchers who looked at the medical records of more than 3-thousand VA patients say within three months of going off the drug there was a significantly higher or nearly double the risk of death or having a heart attack.

Medical groups including the American Heart Association and the American College of Cardiology recently issued guidelines requiring drug-coated stent patients stay on Plavix for at least a year, maybe longer.

The JAMA study suggests those guidelines be revisited and that patients may need to stay on Plavix indefinitely, similar to people who take an aspirin a day to try to stave off a heart attack.

Plavix is among the top-selling drugs in the world.  One of the authors of the study has received funding from BMY and SNY.

© 2009 CNBC.com
Tools:
Print EmailAdd This share icon

Current DateTime: 06:29:15 16 Nov 2009
LinksList Documentid: 29016957
Expiration DateTime: 11/16/2009 6:30:57 PM

Current DateTime: 06:29:15 16 Nov 2009
LinksList Documentid: 29017287
Expiration DateTime: 11/16/2009 6:30:27 PM


Current DateTime: 01:12:16 16 Nov 2009
LinksList Documentid: 29778428

Current DateTime: 10:28:53 16 Nov 2009
LinksList Documentid: 29779196

Current DateTime: 04:01:03 16 Nov 2009
LinksList Documentid: 29779199

Current DateTime: 10:42:55 16 Nov 2009
LinksList Documentid: 29779198
  Data is a real-time snapshot  *Data is delayed at least 15 minutes
Global Business and Financial News, Stock Quotes, and Market Data and Analysis

© 2009 CNBC, Inc.  All Rights Reserved.
A Division of NBC Universal
Thomson ReutersThomson Reuters